journal article·2024-10

Nanoparticles target M2 macrophages to silence kallikrein-related peptidase 12 for the treatment of tuberculosis and drug-resistant tuberculosis

Yuanzhi Wang, Yiduo Liu, Meizhen Long, Yuhui Dong, Lin Li, Xiangmei Zhou

Acta Biomaterialia· Volume 188
Publisher page

Abstract

Matrix metalloproteinases (MMPs) are involved in the breakdown of lung extracellular matrix and the consequent release of Mycobacterium tuberculosis into the airways. Recent studies indicate that kallikrein-related peptidase 12 (KLK12) regulate MMP-1 and MMP-9, suggesting that targeting the KLK12 gene could be a promising tuberculosis (TB) treatment. To maximise therapeutic potential, this strategy of silencing KLK12 needs to be delivered to the pathogenic cell population while preserving the immunoprotective and tissue homeostatic functions of other lung macrophages. Our research found that KLK12 is highly expressed in M2 macrophages, leading us to design mannose-based bovine serum albumin nanoparticles (MBNPs) for delivering siRNA to silence KLK12 in these cells. The results of in vitro experiments showed that MBNPs could accurately enter M2 macrophages and sustainably release KLK12-siRNA with the help of mannose and mannose receptor targeting. The results of the in vivo experiments showed that MBNPs could reach the lungs within 1 h after intraperitoneal injection and peaked at 6 h. MBNPs increased collagen fibre content in the lungs by decreasing the levels of KLK12/MMPs thereby limiting the progression of TB. Importantly, MBNPs provided greater alleviation of pulmonary TB symptoms and reduced bacterial load in both TB and drug-resistant TB models. These findings provide an alternative and effective option for the treatment of TB, especially when drug resistance occurs. STATEMENT OF SIGNIFICANCE: RNA interference using small interfering RNA (siRNA) can target various genes and has potential for treating diseases such as tuberculosis (TB). However, siRNAs are unstable in the blood and within cells. This study presents bovine serum albumin nanoparticles encapsulating KLK12-siRNA (BNPs) synthesized via desolvation. A mannose layer was added (MBNPs) to target mannose receptors on M2 macrophages, facilitating endocytosis. The low pH-responsive MBNPs enhance lysosomal escape for siRNA delivery, downregulating the KLK12 pathway. Tests confirmed that MBNPs effectively inhibited Mycobacterium bovis proliferation, reduced granulomas, and decreased inflammation in a mouse model. This research aims to reduce antibiotic use, shorten treatment duration, and provide a novel TB treatment option.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Peptidase Inhibition and Analysis · Pneumocystis jirovecii pneumonia detection and treatment · Coagulation, Bradykinin, Polyphosphates, and Angioedema

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (70)

Show source-provided references
1. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review10.1371/journal.pone.0017601 ↗
2. WHO's Global Tuberculosis Report 202210.1016/S2666-5247(22)00359-7 ↗
3. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies10.1016/S1473-3099(18)30110-5 ↗
4. Tuberculosis–advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers10.1016/S1473-3099(16)00070-0 ↗
5. Towards host-directed therapies for tuberculosis10.1038/nrd4696 ↗
6. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation10.1183/09031936.00127807 ↗
7. Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection10.1128/IAI.02048-05 ↗
8. Mycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation10.1002/path.4432 ↗
9. Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury10.1165/rcmb.2009-0034OC ↗
10. Adjunct antibody administration with standard treatment reduces relapse rates in a murine tuberculosis model of necrotic granulomas10.1371/journal.pone.0197474 ↗
11. Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology10.1093/infdis/jiy373 ↗
12. KLK12 Regulates MMP-1 and MMP-9 via Bradykinin Receptors: Biomarkers for Differentiating Latent and Active Bovine Tuberculosis10.3390/ijms232012257 ↗
13. Astrocyte-leucocyte interactions and the mechanisms regulating matrix degradation in CNS tuberculosis10.1042/BST0350686 ↗
14. Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance10.1183/09031936.00146510 ↗
15. Metalloproteinases in biology and pathology of the nervous system10.1038/35081571 ↗
16. Targeting macrophages using nanoparticles: a potential therapeutic strategy for atherosclerosis10.1039/D0TB02956D ↗
17. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis10.1038/s41569-021-00629-x ↗
18. Macrophage: A Cell With Many Faces and Functions in Tuberculosis10.3389/fimmu.2022.747799 ↗
19. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity10.1006/smim.1998.0141 ↗
20. The mannose receptor ligands and the macrophage glycome10.1016/j.sbi.2022.102394 ↗
21. Mannose Ligands for Mannose Receptor Targeting10.3390/ijms25031370 ↗
22. Nanoparticles–a new colloidal drug delivery system
23. Bovine Serum-Albumin Is a Major Oligonucleotide-Binding Protein Found on the Surface of Cultured-Cells10.1089/ard.1995.5.213 ↗
24. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide10.1016/S0378-5173(02)00300-9 ↗
25. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide10.1016/j.jconrel.2003.10.009 ↗
26. A Near-Infrared Laser-Activated "Nanobomb" for Breaking the Barriers to MicroRNA Delivery10.1002/adma.201600213 ↗
27. Recent progress in development of siRNA delivery vehicles for cancer therapy10.1016/j.addr.2016.06.011 ↗
28. Unique Intercellular Delivery Vehicles10.1016/j.tcb.2016.11.003 ↗
29. Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy10.1155/2011/742895 ↗
30. A Single ssDNA Aptamer Binding to Mannose-Capped Lipoarabinomannan of Bacillus Calmette-Guerin Enhances Immunoprotective Effect against Tuberculosis10.1021/jacs.6b05357 ↗
31. Selection and identification of specific glycoproteins and glycan biomarkers of macrophages involved in Mycobacterium tuberculosis infection10.1016/j.tube.2017.03.010 ↗
32. Modulation of macrophage phenotype by cell shape10.1073/pnas.1308887110 ↗
33. A completed KLK activome profile: investigation of activation profiles of KLK9, 10, and 1510.1515/BC.2009.026 ↗
34. Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis10.1111/cpr.12649 ↗
35. Protein-Based Nanoparticles as Drug Delivery Systems10.3390/pharmaceutics12070604 ↗
36. Albumin-based nanoparticles as potential controlled release drug delivery systems10.1016/j.jconrel.2011.07.031 ↗
37. Purification and characterization of the D-mannose receptor from J774 mouse macrophage cells10.1016/S0008-6215(00)90605-0 ↗
38. Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy10.1039/C7SC04853J ↗
39. Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis10.1073/pnas.2121098119 ↗
40. Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS-) vs. Alternatively Activated Macrophages10.3389/fimmu.2020.00234 ↗
41. RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?10.1146/annurev-pharmtox-010715-103633 ↗
42. Albumin Microspheres as a Drug-Delivery System - Relation among Turbidity Ratio, Degree of Cross-Linking, and Drug-Release10.1023/A:1018979126326 ↗
43. Inhibition of aberrant tissue remodelling by mesenchymal stromal cells singly coated with soft gels presenting defined chemomechanical cues10.1038/s41551-021-00740-x ↗
44. Matrix Metalloproteinases in Pulmonary and Central Nervous System Tuberculosis-A Review10.3390/ijms20061350 ↗
45. N.C.f.H.I.V.S.T.D. Division of Tuberculosis Elimination, C.f.D.C. Tb Prevention, Prevention, Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States
46. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali10.1016/j.ijid.2019.02.004 ↗
47. Targeting the kallikrein-related peptidases for drug development10.1016/j.tips.2012.09.005 ↗
48. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy10.1016/j.actbio.2021.12.019 ↗
49. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia10.1016/j.eururo.2010.11.024 ↗
50. KLK12 is a novel serine protease and a new member of the human kallikrein gene family - Differential expression in breast cancer10.1006/geno.2000.6346 ↗
51. Precision arrows: Navigating breast cancer with nanotechnology siRNA10.1016/j.ijpharm.2024.124403 ↗
52. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells10.1038/s41467-017-00297-x ↗
53. Nanotechnology-based drug delivery systems10.1186/1745-6673-2-16 ↗
54. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice10.1128/AAC.34.6.967 ↗
55. Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation10.1080/08982100802610835 ↗
56. Tuftsin-bearing liposomes as antibiotic carriers in treatment of macrophage infections10.1016/S0076-6879(05)91016-1 ↗
57. Delivery of liposomes in dry powder form: aerodynamic dispersion properties10.1016/j.ejps.2003.09.008 ↗
58. Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages10.1016/j.carbpol.2020.116978 ↗
59. Advanced materials for co-delivery of drugs and genes in cancer therapy10.1002/adhm.201200109 ↗
60. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug10.1021/bm801109g ↗
61. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis10.1016/j.ijantimicag.2005.07.012 ↗
62. Oral solid lipid nanoparticle-based antitubercular chemotherapy10.1016/j.tube.2005.08.009 ↗
63. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis10.1093/jac/dkg477 ↗
64. Preparation of hydrophobic and hydrophilic albumin microspheres and determination of surface carboxylic acid and amino residues10.1016/S0378-5173(97)04886-2 ↗
65. Desolvation process and surface characteristics of HSA-nanoparticles10.1016/S0378-5173(99)00420-2 ↗
66. Precise targeting of as a therapeutic strategy for human triple negative breast cancer10.1038/s41565-019-0381-6 ↗
67. siRNA nanoparticles targeting CaMKIIgamma in lesional macrophages improve atherosclerotic plaque stability in mice10.1126/scitranslmed.aay1063 ↗
68. Vascular endothelial growth factor levels in active pulmonary tuberculosis10.1378/chest.125.6.2156 ↗
69. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease10.1152/ajplung.00163.2007 ↗
70. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy10.1038/nm.3791 ↗